• Hainan Sihuan was founded
  • Acquired 28% interest in Beijing Sihuan
  • Launched Kelinao and Chuanqing
  • Granted a 20-year patent for the chemical synthesis process for Cinepazide Maleate (API of Kelinao)
  • Entered into a JV to establish Hainan Sihuan CVD Research
  • Beijing Sihuan became the wholly owned subsidiary of the Company
  • Achieved #1 CCV market share for the first time
  • Sihuan was listed in Singapore on 23 March 2007
  • Acquired 60% interest in KBP BioSciences
  • Launched Aogan
  • Launched Qingtong
  • Delisted from Singapore
  • Morgan Stanley became our shareholder.
  • Listed on the mainboard of Hong Kong Stock Exchange
  • Acquired 100% interests of Dupromise
  • Acquired the 30-year exclusive distribution rights for Alprostadil
  • Key products acquired:
    - Oudimei (Cerebroside-Kinin Injection)
    - Yuanzhijiu (Troxerutin and Cerebroprotein Hydrolysate Injection)
    - Fufangsanwei B Injection (II) (Compound Trivitamin B for Injection (II)
    - Yimaining ( Alprostadil lipid emulsion Injection)
  • Acquired 80% interest of Changchun Xiangtong Pharmaceutical
  • Acquired 100% interests of Vinise Pharmaceutical,Disposed 50% equity interest in Vinise Pharmaceutical to ShandongBuchang Pharmaceutical
  • Key products acquired:
    - GM1 injections and API
    - Breviscapine and Sodium Chloride injections
    - Scutellarin Glucose injections
    - Salviae Miltiorrhizae and Ligustrazine injections
    - Salivae Miltiorrhizae Liguspyragine Hydrochloride and Glucose injections
  •  Collaborated with Swedish company NeuroViveAB to develop two innovative CCV drugs
  •  Aquired remaining 40% equity interest in Xuanzhu Pharma to consolidate R&D resources
  •  Langfang Gaobo Jingband was granted the "High and New Technology Enterprise" status
  •  3 Category 1.1 innovative drugs received Clinical Trial Approval
  •  First-to-market exclusive drug Roxatindine was launched
  •  Langfang Gaobo Jingband received the Estanlishment Inspection Report(EIR) issued by the U.S. FDA
  •  The Investigational New Drug(IND)application of Pirorinib(the first self-developed oncology drug of the Group) was successfully submitted to the U.S. FDA and the clinical trial approval was granted
  •  Tylerdipine Hydrochloride(the internally developed innovative antihypertensive drug) received clinical trial approval